Omeros | OMER - Interest Expense On Debt


Omeros reported $4.05M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Adma Biologics USD 1.63M 54K Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Cytokinetics USD 30.33M 4.01M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Immunic 400K 400K Dec/2024
Insmed USD 20.6M 217K Dec/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.89M 387K Dec/2025
Pfizer USD 711M 59M Dec/2025
Rockwell Medical USD 232K 199K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024